The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

may be an advanced form of macular degeneration, or loss of vision. Geographic atrophy, also known as GA, is a form of advanced dry macular degeneration where patients can develop vision loss from ...

INR:0323. today test result Novartis' SMA gene therapy Zolgensma, the world's most expensive drug, is included in UK health insurance Positive data from Phase I ...

CQ9 slot online These 4 technologies will change the future of cancer treatment Positive data from Phase IIb trial of Zimura for the treatment of advanc ...

blackjack games Positive data from Phase IIb trial of Zimura for the treatment of advanced dry age-related macular degeneration Well-known pharmaceutical company deregisters two companies These ...

bet winner app 『Pharmaceutical Headlines』Hubei launches a large-scale inspection of pharmacies and the curtain has been raised on comprehensive drug monitoring Medical Talent Recruitment (Updated on 9 ...

Class 1 new drugs approved for clinical trials, from Sanofi, Impa Pharmaceuticals and other companies \| CDE Weekly Positive ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...